Welcome
Support Centre
29 August 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Warning Time and Patient Centred Goals with Transdermal Oxybutynin
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN87161129
Date ISRCTN assigned24/11/2005
Local reference number(s)EUDRACT 2005-005009-41
Public titleWarning Time and Patient Centred Goals with Transdermal Oxybutynin
Scientific title
AcronymWTPCGTO
Disease/condition/study domainOveractive bladder
Study hypothesisTransdermal oxybutynin reduces urinary warning time, and helps patients achieve their goals for treatment.
Design/methodologyDouble-blind randomised controlled trial (RCT)
Research ethics reviewPending from King's College Hospital Research Ethics Committee
Countries of trialUnited Kingdom
Participants - inclusion criteriaAt study entry:
1. Female patient aged ≥18
2. Written informed consent obtained
3. Patient is willing and able to complete the frequency volume chart (FVC) and questionnaires correctly
4. Symptoms of overactive bladder (frequency/urge/urge incontinence) for ≥3 months AND/OR previously demonstrated detrusor overactivity (DO) at urodynamics

At randomisation:
1. At least three episodes of urgency or urge incontinence on FVC over 3 days
2. At least frequency ≥8 on FVC over 3 days
Participants - exclusion criteriaAt study entry:
1. History of allergy to oxybutynin or any of the ingredients of Kentera
2. History of allergy from medical tape or transdermal skin patch
3. Pregnancy, intention to become pregnant during study period, unreliable contraception despite being sexually active, breast feeding
4. Urodynamic proven mixed incontinence
5. Voiding difficulties (flow rate <15 ml/s, or post void residual >50 ml)
6. Patient with indwelling catheter or practicing clean intermittent self-catheterisation (CISC)
7. Evidence of current urinary tract infection (UTI) or bladder stone or malignancy
8. Uncontrolled narrow angle glaucoma, myasthenia gravis, gastric or urinary retention, renal impairment or dialysis, moderate or severe hepatic impairment, chronic intestinal disease (including ulcerative colitis and gastrointestinal obstruction), megacolon, diabetic neuropathy, oesophageal inflammation (hiatus hernia, gastrooesophageal reflux), Parkinson’s disease, or other significant clinical condition (at the discretion of the investigator)
9. Other specific medications: anticholinergics, antispasmodics, anti-parkinsonian, tricyclics, tetracyclics, duloxetine, antihistamines, antiemetics, diuretics, neuroleptics, type I antiarrythmics, opioids, alpha-antagonists, CYP3A4 inhibitors or inducers, any other bladder medication

At randomisation:
Failure to complete FVC according to instructions
Patient information material
Anticipated start date01/12/2005
Anticipated end date01/12/2007
Status of trialCompleted
Target number of participants96
InterventionsTransdermal Oxybutynin or Placebo Patch
Primary outcome measure(s)Achievement of goals score.
Secondary outcome measure(s)1. Change in KHQ scores (by domain and total)
2. Change in mean, median and minimum warning time
3. Compliance with medication
4. Change in episodes of urgency/urge incontinence
5. Change in frequency/nocturia
Sources of fundingUCB Pharma - an investigator initiated study, meaning that investigators will 'own' the data, but UCB Pharma are funding on the assumption that the publication of the results will be of commercial benefit to them.
Sponsor nameKing's College London (UK)
Sponsor detailsProf Linda Cardozo
8 Devonshire Place
London
United Kingdom
W1G 6HP
Contact nameProf Linda Cardozo
Contact details8 Devonshire Place
London
United Kingdom
W1G 6HP
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN87161129
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central